STOCK TITAN

NanoString to Webcast Presentation from 42nd Annual J.P. Morgan Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
NanoString Technologies, Inc. (NSTG) to present at the 42nd annual J.P. Morgan healthcare conference. Brad Gray, president and CEO, to present on January 10, 2024, at 5:15pm ET. Webcast available on company website.
Positive
  • None.
Negative
  • None.

SEATTLE--(BUSINESS WIRE)-- NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today announced that company management is scheduled to webcast a presentation from the 42nd annual J.P. Morgan healthcare conference, being held January 8-11, 2024.

Brad Gray, president and chief executive officer, is scheduled to present on Wednesday, January 10, at 5:15pm ET. Interested parties can access the live webcast from the investor section of the company’s website at www.nanostring.com. The webcast replay will be available one hour after the conclusion of the live presentation and archived for 30 days.

About NanoString

NanoString Technologies, a leader in spatial biology, offers an ecosystem of innovative discovery and translational research solutions, empowering our customers to map the universe of biology. The GeoMx® Digital Spatial Profiler is a flexible and consistent solution combining the power of whole tissue imaging with gene expression and protein data for spatial whole transcriptomics and proteomics. The CosMx™ Spatial Molecular Imager is a single-cell imaging platform powered by spatial multiomics enabling researchers to map single cells in their native environments to extract deep biological insights and novel discoveries from one experiment. The AtoMx™ Spatial Informatics Platform is a cloud-based informatics solution with advanced analytics and global collaboration capabilities, enabling powerful spatial biology insights anytime, anywhere. At the foundation of our research tools is our nCounter® Analysis System, which offers a secure way to easily profile the expression of hundreds of genes, proteins, miRNAs, or copy number variations, simultaneously with high sensitivity and precision.

For more information, please visit www.nanostring.com.

NanoString, NanoString Technologies, the NanoString logo, GeoMx, AtoMx and nCounter are trademarks or registered trademarks of NanoString Technologies, Inc. in various jurisdictions.

Doug Farrell

Vice President, Investor Relations & Corporate Communications

dfarrell@nanostring.com

Phone: 206-602-1768

Source: NanoString Technologies, Inc.

FAQ

When is NanoString Technologies, Inc. (NSTG) presenting at the 42nd annual J.P. Morgan healthcare conference?

NanoString Technologies, Inc. (NSTG) is scheduled to present on Wednesday, January 10, at 5:15pm ET.

Who will be presenting for NanoString Technologies, Inc. (NSTG) at the conference?

Brad Gray, president and CEO, will be presenting.

Where can interested parties access the live webcast?

Interested parties can access the live webcast from the investor section of the company’s website at www.nanostring.com.

When will the webcast replay be available?

The webcast replay will be available one hour after the conclusion of the live presentation and archived for 30 days.

NanoString Technologies, Inc.

NASDAQ:NSTG

NSTG Rankings

NSTG Latest News

NSTG Stock Data

5.07M
39.41M
3.17%
106.45%
12.55%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
US
Seattle

About NSTG

nanostring technologies (nasdaq: nstg) is a publicly held provider of life science tools for translational research and molecular diagnostics. the company's technology enables a wide variety of basic research, translational medicine and in vitro diagnostics applications. nanostring technologies provides life science tools for translational research and molecular diagnostic products. the company's ncounter® analysis system, which has been employed in basic and translational research since it was first introduced in 2008 and cited in more than 300 peer-reviewed publications, has also now been applied to diagnostic use as the ncounter dx analysis system. the company's technology offers a cost-effective way to easily profile the expression of hundreds of genes, mirnas, or copy number variations, simultaneously with high sensitivity and precision. the company's technology enables a wide variety of basic research and translational medicine applications, including biomarker discovery and vali